Company Profile
Spero Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Spero Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Spero Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Spero Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Spero Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
SPRO is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Spero Therapeutics’s catalysts are tebipenem HBr and any regulatory or partnering step that keeps the oral-carbapenem story alive. The company needs a cleaner development path to re-rate the name.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update
Source: Spero Therapeutics
- 03
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Source: Spero Therapeutics
- 04
Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference
Source: Spero Therapeutics
- 05
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
Source: Spero Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.